Venquis Therapeutics has developed a small molecule monovalent degrader discovery platform named CIPD, which targets clinically relevant proteins in a mutant-selective fashion for the treatment of oncology and other diseases.

Venquis Therapeutics

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 5:58 AM	d750f017
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 5:58 AM	94bc811f
crunchbase trigger	general	Nov 27, 2024 12:50 PM	e7afc59c
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 16, 2024 5:58 AM	17b69040
news basic	general	Oct 16, 2024 5:58 AM	4a18fda0
bundesanzeiger	filings
financials download nd	financials
private financials	financials

VENQ

COM:VENQUISTX

Venquis Therapeutics